文献速递脑血管病外科神经重症

家庭用药对动脉瘤性蛛网膜下腔出血后迟发性脑缺血风险的影响

The impact of home medications on the risk of delayed cerebral ischemia after aneurysmal subarachnoid hemorrhage.
PubMed 文献 · Acta Neurochir (Wien) · 2025-11-26

该回顾性研究纳入995例动脉瘤性蛛网膜下腔出血患者,分析家庭用药与脑梗死及功能结局的关联。结果显示钙通道阻滞剂(CCB)使用与迟发性脑缺血(DCI)风险(aOR=4.05)和6个月功能残疾(aOR=2.73)独立相关,早期梗死无关联。

要点

  • 规律使用CCB与DCI风险升高独立相关(aOR=4.05)。
  • CCB使用与6个月功能残疾独立相关(aOR=2.73)。
  • 家庭用药与早期梗死(72小时内)无关联。

核心结论

  • 规律使用CCB与动脉瘤性SAH后DCI风险及6个月功能残疾独立相关。

研究设计与样本

  • 回顾性分析纳入2003年1月至2016年6月单中心治疗的995例动脉瘤性SAH患者。

主要发现

  • CCB使用组(n=93)DCI发生率32.6% vs 19.3%(p=0.005)。
  • CCB使用组6个月功能残疾率57.8% vs 46.8%(p=0.048)。
  • 多变量分析中CCB使用与DCI独立相关(aOR=4.05;p<0.0001)。
  • 多变量分析中CCB使用与6个月功能残疾独立相关(aOR=2.73;p=0.036)。
  • 早期梗死(SAH后72小时内)与规律用药无关联。

关键数值与推荐

  • DCI相关梗死定义为随访CT显示SAH后>72小时的新发梗死。
  • 功能残疾定义为6个月时改良Rankin量表>2。

临床怎么用

  • 对动脉瘤性SAH患者应关注家庭CCB使用史,评估DCI与功能结局风险。
  • CCB使用与不良结局的关联需谨慎解读,尚不能据此改变临床用药。

局限性

  • 回顾性设计可能引入偏倚。
  • 作者指出结果需前瞻性研究进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Delayed cerebral ischemia (DCI) is one of the most severe complications following aneurysmal subarachnoid hemorrhage (SAH) and can significantly worsen clinical outcomes. This study aimed to analyze the association between patients' home medications and the risk of cerebral infarction and poor functional outcomes after SAH. METHODS: This retrospective analysis included 995 patients with aneurysmal SAH treated at our clinic between January 2003 and June 2016. Various demographic and clinical baseline characteristics were examined, with a particular focus on regular use of home medications. The study endpoints were the occurrence of early (within 72 h post-SAH) and DCI-related infarcts (> 72 h) in follow-up computed tomography scans, as well as the functional disability at six months, defined as a modified Rankin Scale > 2. RESULTS: There was no association between the occurrence of early infarcts and patients' regular medications. In contrast, individuals with calcium channel blockers (CCB) use (n = 93) showed a higher rate of DCI (32.6% vs 19.3%, p = 0.005) and 6-months functional disability (57.8% vs 46.8%, p = 0.048). In multivariable analysis, CCB use was independently associated with the risk of DCI (adjusted odds ratio [aOR] = 4.05; p < 0.0001) and functional disability after six months (aOR = 2.73; p = 0.036). CONCLUSIONS: Regular CCB use was independently associated with an increased risk of DCI and functional disability at six months. These findings warrant cautious interpretation and further validation in prospective studies.

来源:Acta Neurochir (Wien),查看原文。版权归原作者所有。

引用

  1. Ketelauri P, Gümüs M, Karadachi HH, et al. The impact of home medications on the risk of delayed cerebral ischemia after aneurysmal subarachnoid hemorrhage. Acta Neurochir (Wien). 2025. PMID: 41298953. doi:10.1007/s00701-025-06730-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。